RhIL-11 treatment normalized Th1/Th2 and T-bet/GATA-3 imbalance in in human immune thrombocytopenic purpura (ITP)
详细信息 查看全文
- 作者：Ying Lin<sup>asup> ; Xieming Zhou<sup>bsup> ; Wenjian Guo<sup>asup> ; Qianqian Li<sup>asup> ; Xiahui Pan<sup>asup> ; Yunhua Bao<sup>csup> ; Muqing He<sup>asup> ; Baoling Zhu<sup>asup> ; Xiaoji Lin<sup>asup> ; Limin Jin<sup>asup> ; Rongxin Yao<sup>asup><sup> ; sup><sup>yaorongxin@126.com" class="auth_mail" title="E-mail the corresponding authorsup>
- 关键词：Immune thrombocytopenic purpura ; IL-11 ; T-bet ; GATA-3 ; Th1 ; Th2
- 刊名：International Immunopharmacology
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：38
- 期：Complete
- 页码：40-44
- 全文大小：478 K
文摘
- •
RhIL-11 treatment was effective with tolerable adverse effects in ITP.
- •
RhIL-11 decreased Th1 and T-bet levels whereas increased Th2 and GATA-3 levels in vivo.
- •
RhIL-11 effectively restored disturbed Th1/Th2 and T-bet/GATA-3 ratio in ITP patients.